Last reviewed · How we verify
QL0605
At a glance
| Generic name | QL0605 |
|---|---|
| Also known as | pegfilgrastim |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints (PHASE4)
- A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QL0605 CI brief — competitive landscape report
- QL0605 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI